Phase II study of pentosan polysulfate (PPS) in patients with AIDS-related Kaposi's sarcoma.
OBJECTIVE
To evaluate the response rate, toxicity and survival of patients with AIDS-related Kaposi's sarcoma (AIDS-KS) treated in a phase II clinical trial of pentosan polysulpate (PPS), an inhibitor of basic-fibroblast growth factor (b-FGF) which blocks the growth of Kaposi's sarcoma cells both in culture and in animal models.


METHODS
Between March 1992 and March 1994 16 homosexual males with histopathologically confirmed AIDS-KS were accrued for this phase II clinical trial. PPS was administered at the dose of 25 mg/m2 q6 hrs at day 1, followed by 25 mg/m2 q12 hrs daily by a subcutaneous injection. The number of patients to be included in the trial was calculated according to the two-stage Gehan method. Toxicity was graded according to the NCl Common Toxicity Criteria, while responses were evaluated according to the WHO Criteria adapted for KS lesions. Patients were all homosexual males, median age 35 (27-43) years, performance status (WHO) 1 (0-2), NYU stage II-IV and prior therapy included vincristine and etoposide (3 cases), local irradiation (4 cases) and megestrol acetate (2 cases). Concomitant AZT (zidovudine) was given to 3 patients, while DDI (dideoxyinosine) was administered in one case.


RESULTS
A median of 5 (3-11) weeks of therapy was administered to the patients. Pain at the injection site and low grade fever were the only toxicities observed. Drug-related effects on coagulation parameters or thrombocytopenia were not observed in the trial. One objective response (6%) was documented, which lasted for 9 weeks, while stable disease was observed in three patients, lasting for 11, 9 and 5 weeks, respectively.


CONCLUSIONS
This is the first observation of objective antitumor activity with a b-FGF inhibitor in patients with AIDS-KS. Considering it novelty and the lack of significant toxicity, the authors suggest that this experimental approach deserves further evaluation.
Department of Medical Oncology, Academic Hospital of Porto Alegre (HCPA), Federal University of Rio Grande do Sul, Brazil.
G
G
Schwartsmann
E
E
Sprinz
L
L
Kalakun
N
N
Yamagushi
E
E
Sander
I
I
Grivicich
R
R
Koya
D R
DR
Mans
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000209:etiology; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D016222:Fibroblast Growth Factor 2 / Q000037:antagonists & inhibitors*; D018451:Homosexuality, Male; D006801:Humans; D008297:Male; D010426:Pentosan Sulfuric Polyester / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012514:Sarcoma, Kaposi / Q000821:virology*; D016019:Survival Analysis; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D016222:Fibroblast Growth Factor 2; D010426:Pentosan Sulfuric Polyester